Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Diflucan

Executive Summary

Oral antifungal fluconazole is "at least as effective and may be superior" to the standard treatment of I.V. amphotericin B in preventing recurrences of AIDS-related cryptococcal meningitis, HHS announced May 11. Conclusion was based on suspended U.S. multicenter trials of 205 patients conducted by Pfizer, the National Institute for Allergy and Infectious Disease AIDS Clinical Trials Group and its Mycoses Study Group. NIAID, based on preliminary results of the study, now recommends that Diflucan replace amphotericin B (Bristol-Myers Squibb's Fungizone) for the recurrence prevention treatment. Diflucan, in oral and I.V. forms, was approved Jan. 29 ("The Pink Sheet" Feb. 5, p. 5).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017431

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel